%PDF-1.4
%
7 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
11 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
13 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
8 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
12 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
15 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
3 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
6 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
14 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
1 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
5 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
9 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
10 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
4 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
17 0 obj
<>stream
application/pdf10.1080/14737167.2016.1208087application/pdf10.1080/14737167.2016.1208087enAn estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
Nathalie LargeronKarl Ulrich PetryJorge JacobFlorence BianicDelphine AngerMathieu Uhart
Taylor & Francis
Expert Review of Pharmacoeconomics & Outcomes Research, 2016. doi:10.1080/14737167.2016.1208087
Cost-effectivenessGermanyHPVcervical cancervaccination
10.1080/14737167.2016.1208087http://dx.doi.org/10.1080/14737167.2016.12080872016-07-15truewww.tandfonline.com10.1080/14737167.2016.1208087www.tandfonline.comtrue2016-07-1510.1080/14737167.2016.1208087application/pdf10.1080/14737167.2016.1208087enAn estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
Nathalie LargeronKarl Ulrich PetryJorge JacobFlorence BianicDelphine AngerMathieu Uhart
Taylor & Francis
Expert Review of Pharmacoeconomics & Outcomes Research, 2016. doi:10.1080/14737167.2016.1208087
Cost-effectivenessGermanyHPVcervical cancervaccination
JournalExpert Review of Pharmacoeconomics & Outcomes Research© 2016 Informa UK Limited, trading as Taylor & Francis Group1473-71671744-8379000011410.1080/14737167.2016.1208087http://dx.doi.org/10.1080/14737167.2016.1208087
VoR
2016-07-14T05:55:12+05:30Arbortext Advanced Print Publisher 11.0.3352/W Unicode2016-10-21T00:57:30-07:002016-10-21T00:57:30-07:00
Cost-effectiveness; Germany; HPV; cervical cancer; vaccinationiText 4.2.0 by 1T3XT
uuid:7fe07a57-7df3-48a3-9adb-2e37120391ebuuid:10d78ad1-a67b-4839-89a1-7d1177ec08f9
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bih W
endstream
endobj
28 0 obj
<>stream
x+ |
endstream
endobj
29 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 Bih uU
endstream
endobj
34 0 obj
<>stream
x+ |
endstream
endobj
35 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
36 0 obj
<>stream
x+ |
endstream
endobj
37 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
38 0 obj
<>stream
x+ |
endstream
endobj
39 0 obj
<>stream
xS**T0T0 Bih ~V
endstream
endobj
40 0 obj
<>stream
x+ |
endstream
endobj
41 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
42 0 obj
<>stream
x+ |
endstream
endobj
43 0 obj
<>stream
xS**T0T0 Bih lT
endstream
endobj
44 0 obj
<>stream
x+ |
endstream
endobj
45 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
46 0 obj
<>stream
x+ |
endstream
endobj
47 0 obj
<>stream
xS*
R
endstream
endobj
49 0 obj
<>stream
xZI\G ˴C2 j9r8??U*Qf$ 4-d6?25~ AC҉^pnޥZc}/?c1_7&W*Uo>'J{kx:=|9Ooys:>HqigiuqLǛGuI-!hZLaac@}mw+ș}7COjeBZ4èi#_@g3Z8$4=?e5+p oMXm{I!aSd]vf]A&u1 ԘBFGQ'ju5z%\H@A\ۂp{YFzu%Z֑^U
Z툲
lqբ`vS4N%Q
4KH̯3 ^kFgohnHݹaϰ oeMF65 Q|ƫ6Yx``eg-kMJS Eef&]L
t(p88Vd 9VȓE'B /X敇 o\*uBxÀ `) \(/[D1lA#;hBAP
=]{ .Nb<-N!RaPE
V.
m7;jכ:N
fkO$ufk[f0kW5l1SM\a@={+)]`*81dkA䀀KָbsRF@mŒiARr&=OL/#^^
POhuSFT*ok=,W!
l8m=Mc}ЌeI<\f;40 0ZO7UB1/J9yo[?=Eq}C$a?#I9l3IY2fd0$m1bוvaVDٹϟ/mE9e,krqzu48sdȖ9H֛-]r'̮;42ح4HLUTL"d8k"-6c |_vNRl 4ˇ4a-뱗kz۵H@QbRS FN2-tG;E
,ʠEmc)RJ']D!\:P֏cn Ҡv4,4Pq+p;
Ю62-p%()toW%Z(|zpɫ?'/\fd͎EvPbn9뀊bi*v+9BRtװ{iXfu!\]nHv
x44G* wf
eϰB? ˕a˴ȉk Fuc9, iv_Sbg;-Bc2G@B'FD ֤w-y8ݚTVWNsgBV tl%pŽhRsJCPga/`kF[IypL9";+)
4C};?;%F|7*ZT[j\|(,_YD,a:uYWlva5ڃ:}aY'_>B/GCAsb&1
KKbA}'9=hS]!.^%80d`Ac5R`f2n"
P
2_D
#rW֊9
9*j]{_Nj#Ed81T[n98Ac-{4oV,dY9wԂ
ðpgXi9T>|`$80;"QӡCA^gcmh0YzsǨd#)'Y[6]K[VҊ?FAOy?p$#Kb8nΤӓ8rhT}lޤ;uڞat)Ņ=ǭ]r+z̻3Tַ
4]᱒oD/7rsQ'hJs׆7s[nxeUVNTHku:)EOf3
.MrFWl!I~{ۦ懝^әF;7]"
Yh.˙XzžbT&ܘ
C5ẩtY3?[&Vv
=K`2@sY%7ę:/.[87AI|VKpƻW/ t' ݨ]$>%URlg*S?Nd